The development of vaccines has enabled the successful fight against a wide range of infectious diseases. CD BioGlyco has developed advanced platforms for the design and synthesis of polysaccharide vaccines and polysaccharide conjugate vaccines. We have the confidence to assist our customers in the field of vaccine development.
Capsular polysaccharide (CPS) is a component associated with bacterial cellular immune response and consists of monosaccharides bound together by glycosidic bonds with excellent biocompatibility and unique biological activity. Capsular polysaccharides are excellent targets for bacterial vaccine development, and bactericidal and/or opsonic antibodies against CPS glycotopes can prevent invasive diseases caused by capsular bacteria.
The development of polysaccharide vaccines was greatly facilitated by the approval of a 14-valent capsular polysaccharides conjugated vaccine against Streptococcus pneumoniae developed by Merck Sharp and Dohme in 1977 in the United States. Polysaccharide vaccines stimulate B-cell responses that result in the production of type-specific antibodies, which enhance phagocytic ingestion and killing of pathogens. However, these antigens are not T-cell dependent and therefore do not produce lasting immunity. Studies have shown that coupling bacterial polysaccharides with carrier proteins can generate T-cell-dependent antigens. Therefore, polysaccharide-conjugated vaccines have received a lot of attention from researchers.
Fig.1 The immune mechanism of polysaccharide conjugate vaccine and the difference from polysaccharide vaccine. (Jing, 2020)
CD BioGlyco is dedicated to the development, preparation and quality control of polysaccharide vaccines and polysaccharide conjugate vaccines. Services we provide include but are not limited to:
Vaccines based on purified polysaccharides usually produce insufficient immunity. Vaccines developed by polysaccharides-macromolecular proteins conjugate overcome this shortcoming. Therefore, CD BioGlyco specializes in providing one-stop solutions for polysaccharide conjugation to clients.
As a biotechnology company recognized by our peers and satisfied by our clients in the industry, CD BioGlyco is constantly improving the quality of products and the professionalism of our services. We are pleased to help our customers develop safe and effective vaccines and perform critical quality control tests at each stage of vaccine production. If you are interested in our services, please feel free to contact us.